CBD Oil Brain Cancer

CBDISTILLERY

Buy CBD Oil Online

CBD shows promise for fighting aggressive brain cancer The researchers believe that CBD’s anti-cancer actions target mitochondria — the cell’s energy producing structures — by causing the The ratio of cannabidiol (CBD) to tetrahydrocannabinol (THC) in medicinal cannabis has shown to play a crucial role in improving the physical and functional wellbeing of brain cancer patients, according to newly published findings in a trial funded by BioCeuticals, the practitioner-only arm of Blackmores. There’s conclusive evidence for the use of cannabis and its products, such as cannabis oil and CBD oil, for other therapeutic purposes.

CBD shows promise for fighting aggressive brain cancer

The researchers believe that CBD’s anti-cancer actions target mitochondria — the cell’s energy producing structures — by causing the mitochondria to dysfunction and release harmful reactive oxygen species. The mitochondria (teal color) in a canine cancer cell line are shown after 48 hours of treatment with a nonlethal dose of CBD isolate (40x objective lens). Credit: Chase Gross, Mando Ramirez, Jade Kurihara, Colorado State University

Findings from a new study examining human and canine brain cancer cells suggest that cannabidiol could be a useful therapy for a difficult-to-treat brain cancer. Cannabidiol, or CBD, is a non-psychoactive chemical compound derived from marijuana.

The study looked at glioblastoma, an often-deadly form of brain cancer that grows and spreads very quickly. Even with major advancements in treatment, survival rates for this cancer have not improved significantly.

“Further research and treatment options are urgently needed for patients afflicted by brain cancer,” said Chase Gross, a student in the Doctor of Veterinary Medicine/Master of Science program at Colorado State University. “Our work shows that CBD has the potential to provide an effective, synergistic glioblastoma therapy option and that it should continue to be vigorously studied.”

Mr. Gross was scheduled to present this research at the American Society for Pharmacology and Experimental Therapeutics annual meeting in San Diego this month. Though the meeting, to be held in conjunction with the 2020 Experimental Biology conference, was canceled in response to the COVID-19 outbreak, the research team’s abstract was published in this month’s issue of The FASEB Journal.

Mr. Gross and colleagues examined human and canine glioblastoma cells because the cancer shows striking similarities between the two species. They tested the effects of CBD isolate, which contains 100 percent CBD, and CBD extract, which contains small amounts of other natural occurring compounds such as cannabigerol and tetrahydrocannabinol, or THC.

A bright field microscopy image (10x) illustrating the swollen intracellular vesicles observed after 48 hours of treatment with a lethal dose of CBD (10x objective lens). Swollen vesicles were a hallmark of CBD-induced cell death in all the cell lines studied. Credit: Chase Gross, Mando Ramirez, Colorado State University

“Our experiments showed that CBD slows cancer cell growth and is toxic to both canine and human glioblastoma cell lines,” said Mr. Gross. “Importantly, the differences in anti-cancer affects between CBD isolate and extract appear to be negligible.”

The new work revealed that the toxic effects of CBD are mediated through the cell’s natural pathway for apoptosis, a form of programmed cell death. The researchers also observed that CBD-induced cell death was characterized by large, swollen intracellular vesicles before the membrane begins to bulge and breakdown. This was true for all the cell lines studied.

The researchers believe that CBD’s anti-cancer actions target mitochondria—the cell’s energy producing structures—by causing the mitochondria to dysfunction and release harmful reactive oxygen species. Their experiments showed that cells treated with CBD exhibited significant decreases in mitochondrial activity.

“CBD has been zealously studied in cells for its anticancer properties over the last decade,” said Mr. Gross. “Our study helps complete the in vitro puzzle, allowing us to move forward in studying CBD’s effects on glioblastoma in a clinical setting using live animal models. This could lead to new treatments that would help both people and dogs that have this very serious cancer.”

Next, the researchers plan to transition from cell cultures to animal models to test CBD’s effects on glioblastoma. If the animal studies go well, the work could progress to clinical trials on dogs that are being treated for naturally occurring glioblastoma at the Colorado State University Veterinary Teaching Hospital.

See also  CBD Oil Spray For Pain

Citation: CBD shows promise for fighting aggressive brain cancer (2020, April 27) retrieved 9 September 2022 from https://medicalxpress.com/news/2020-04-cbd-aggressive-brain-cancer.html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Ratio matters: CBD and THC ratio plays key role improving quality of life in brain cancer patients – BioCeuticals-funded trial

The ratio of cannabidiol (CBD) to tetrahydrocannabinol (THC) in medicinal cannabis has shown to play a crucial role in improving the physical and functional wellbeing of brain cancer patients, according to newly published findings in a trial funded by BioCeuticals, the practitioner-only arm of Blackmores.

The 12-week double-blind RCT was conducted on 88 patients suffering from high-grade glioma – an aggressive brain cancer with a survival rate of six to 18 months.

Results from MRI scan of 53 participants also showed that 11 per cent of them reported a reduction in disease, 34 per cent were in stable conditions, 16 per cent had slight enhancement, and 10 per cent reported worsening of their condition.

Writing in Frontiers in Oncology, ​the researchers highlighted that a CBD to THC ratio of 1:1 led to more improvements in physical, functional capacities, as well as better sleep quality in these patients, as compared to the use of CBD to THC at the ratio of 1:4.

On the other hand, there was no difference between the two groups in terms of MRI tumour burden/control.

In other words, both ratios exerted similar effects when it comes to affecting the tumour size.

This is also said to be the first study that looked that medicinal cannabis use beyond pain relief and reduction of symptoms.

“Most of the other studies that are done in cancer for medicinal cannabis is actually for symptomatology, which means they are looking at how medicinal cannabis eases pain, nausea and vomiting.

“For this particular study, it was actually trying to look at the quality of life and the patients’ physical functionality, their ability to do everyday things such as walking, the moving of arms and legs, and being able to speak in a sentence.

“It also looked at how medicinal cannabis could enhance the current treatment that these particular patients are undergoing,”​ lead researcher Dr Janet Schloss told NutraIngredients-Asia.

Cannabis derivatives

There’s now conclusive evidence for the use of cannabis-based products for managing the side-effects of a brain tumour.

Cannabis, cannabinoids and cannabis derivatives

Cannabis is the dried preparation, or resinous extract, of the flowers or leaves of the cannabis plant, a member of the hemp family.

The parts of cannabis that are considered important for medical reasons are called cannabinoids. This is the name for the complex chemicals found in cannabis that are responsible for the effect cannabis has on the body. Two cannabinoids are of particular interest:

  • THC – delta-9 tetrahydrocannabinol (responsible for the psycho-active and addictive effects of cannabis)
  • CBD – cannabidiol

Cannabis derivatives is a general term for all products that are produced using different parts of the cannabis plant, including:

  • cannabis-based medicines that certain healthcare professionals can prescribe (for example, Sativex and Nabilone)
  • cannabis products that don’t contain THC, which can be sold legally in the UK as food supplements (for example CBD oil or hemp oil)
  • cannabis products that do contain THC, which are currently illegal in the UK (for example, street cannabis or cannabis oil).

It’s important that you understand the difference between cannabis products that contain CBD and cannabis products that don’t contain THC, as they can have different effects and are legally treated differently.

Our community share their experiences with cannabis-based products

I am having chemotherapy and using CBD oil to help with the side-effects of that.

I used CBD oil to relax and try to reduce my anxiety levels.

See also  CBD Oil And Lyme Disease

I hoped CBD oil would reduce the size of my tumour, however it did grow. I use CBD oil to help with pain, and it makes me calmer and more relaxed.

I have never used cannabis products because my doctor wasn’t sure how it would interact with my other medications.

“I did not use cannabis medicines or products because I didn’t think they would improve or enhance the medication I was receiving.

I believe it can help with nausea, but talk to your doctor first because cannabis can interact with other medications.

These experiences from members of the brain tumour community are not intended as medical advice. Everyone is different and we encourage you to make decisions about using cannabis-products following discussion with your medical team.

Join the conversation in our Online Support Communities for more tips about coping with a brain tumour diagnosis from people who truly understand what you’re going through.

Are cannabis-based products legal in the UK?

Cannabis is an illegal drug in many countries, including the UK, where it is classified as a class B drug. This means it is illegal to posses, supply or produce cannabis in the UK.

Cannabis-based products containing THC (for example, cannabis oil or medical cannabis) are also illegal in the UK, unless you have a valid prescription.

Possession of a class B drug is punishable in the UK with up to 5 years in prison, an unlimited fine or both. Supply and production of a class B drug is punishable with up to 14 years in prison, an unlimited fine or both.

CBD and hemp oils

Cannabis-based products that don’t contain THC (for example, hemp oil or CBD oil) are currently legal in the UK – as long as it has been produced from an EU-approved strain of hemp and as long as it is marketed as a food supplement without any medicinal claims. You can buy these products in many high street health food shops.

Buying cannabis-based products that aren’t from an EU-approved strain of hemp often means you cannot be sure the product is legal in the UK.

What is the evidence for cannabis-based products in the treatment of brain tumours?

Treating brain tumours

Currently, the evidence that cannabis-based products can treat brain tumours themselves is limited.

Preliminary studies from the lab suggest that cannabinoid chemicals THC and CBD can stop glioblastoma (GBM) cells from growing, causing them to die and disrupting the blood supply to the tumour cells.

And, earlier this year, an early-stage trial led by Professor Susan Short suggested that adding a specific blend of these chemicals – in the form of a drug called Sativex – to chemotherapy could potentially help treat recurrent GBMs more effectively.

Treating side-effects

There’s now conclusive evidence for the use of cannabis and its products, such as cannabis oil and CBD oil, for other therapeutic purposes, i.e. pain relief and treating chemotherapy-induced nausea and vomiting.

As such, the cannabis-based drug, Nabilone, has a medical licence and can be legally prescribed for chemotherapy-induced nausea and vomiting.

Cannabis medicines have been used to help with nausea, however these are different to the products that have been tested for use to treat cancers.

Professor Susan Short, Consultant in Clinical Oncology

If you have a question you can’t find an answer to on this page, please contact our Support and Information Line by ringing 0808 800 0004, emailing us at [email protected] or starting a live chat. The Support and Information Line is open Monday to Friday, between 9.00am and 5.00pm.

Is it safe to use cannabis-based products?

Any supplements, alternative or complementary treatments that you or your loved one wish to use could interact with other medications, such as anti-epileptic medicines, steroids or chemotherapy. You should always discuss this with your medical team before deciding to use cannabis-based products.

It is important to be aware that you cannot be sure of the concentrations and ratios of THC and CBD in grown or street cannabis, and therefore cannot guarantee how safe it is. The same is true of other cannabis-products that aren’t prescribed by your healthcare team or produced from an EU-approved strain of hemp.

How safe a cannabis product is will depend on the product itself and the other medications you are taking. You should speak to your medical team for advice before starting cannabis products.

Professor Susan Short, Consultant in Clinical Oncology

Side effects of using cannabis-based medications

Like all medications, cannabis-based medicines have side-effects. These will differ depending on the product you’re using, as well as your individual circumstances.

See also  Eden's Herbals CBD Oil Reviews

Your consultant or medical team will be able to talk to you about possible side-effects as well as how to manage any side-effects you’re experiencing.

The side-effects may vary depending on the product. The common side-effects of Sativex (a cannabis-based medicine) are sickness, tiredness, dizziness and headaches.

Professor Susan Short, Consultant in Clinical Oncology

How can I get cannabis-based products?

Cannabis-based medicines

Only specialist doctors who are listed in the General Medical Council’s (GMC) specialist register will be able to prescribe cannabis-based products. They will only be prescribed when the specialist considers that the patient will benefit and when the patient has an unmet special clinical need that cannot be met by licensed products.

  • Medicinal cannabis, therefore, will be prescribed on a case-by-case basis
  • Patients will NOT be able to get cannabis-based products from their GP
  • If you feel you might benefit from these products, speak to your consultant or healthcare team
  • Administration by smoking remains prohibited.

If you’d like to know more, you could read our blog post on cannabis-based medicinal products or read our information about accessing unlicensed drugs.

CBD and hemp oils

CBD and hemp oils do not contain THC and can be purchased in many high street health food shops.

Cannabis-based medicines are only available through a medical prescription. Cannabis-based products are available without a prescription but many of these are of unknown composition and are not equivalent to medicinal products.

Professor Susan Short, Consultant in Clinical Oncology

Speaking to your medical team about cannabis

We recognise this can be a difficult conversation to start with your, or your loved one’s, medical team. If you are interested in understanding if cannabis-based medications may be suitable for you or your loved one, or if you are considering a non-prescription cannabis product like CBD oil, we recommend you speak with your medical team about this decision.

Cannabis-based medications (medical cannabis) are only likely to be prescribed to a small number of people, and only for specific reasons

Here are some tips to help you have this conversation:

  • Explain why you are interested in cannabis-based medicines or products, and what you are hoping it could do for you or your loved one.
  • Let your medical team know you want them to be involved in decisions about using cannabis-based medicines or products.
  • Ask about research or clinical evidence for or against using cannabis-based medicines or products, and how this relates to your individual circumstances.

Remember, a medical professional’s concern is your health or the health of your loved one. This means they are likely to be open to discussing any medicines or complementary therapies that may be suitable.

Perhaps your medical team will say they don’t recommend any cannabis-based medicines or products for you. You can ask them why. There are often clinical and evidence-based reasons why cannabis-based medicines and products would not be suitable for you or your loved one. For example, because of interactions with other medications.

You may find the UK Medical Cannabis Clinicians Society’s (UKMCCS) guide to medical cannabis helpful when talking to your medical team. It includes information about access, legality, safety and side-effects of medical cannabis.

If you have further questions, need to clarify any of the information on this page, or want to find out more about research and clinical trials, please contact our team:

How useful was this post?

Click on a star to rate it!

Average rating 4 / 5. Vote count: 1

No votes so far! Be the first to rate this post.